Support & Getting Started

Resources

Resources for each step of the treatment journey with AUSTEDO XR

Teva is committed to supporting you, your patients with tardive dyskinesia (TD), and their carepartners.

Downloadable resources

Use this tool for the assessment and routine monitoring of patients at risk of TD.

AIMS Assessment Tool

Use this tool for the assessment and routine monitoring of patients at risk of TD.

IMPACT-TD Scale

A tool developed and published by a consensus panel of experts to help guide the routine monitoring and evaluation of TD impact.

Prescription & Service Request Form for once-daily AUSTEDO XR

Fill out this form to enroll your patient in Teva Shared Solutions^® (for patients taking AUSTEDO XR).

Prescription & Service Request Form for AUSTEDO BID

Fill out this form to enroll your patient in Shared Solutions (for patients taking AUSTEDO BID).

Appeals Letter Template

Use this template to write an appeals letter, which payers may need to appeal a denial of coverage for AUSTEDO^® XR (deutetrabenazine) extended-release tablets or AUSTEDO^® (deutetrabenazine) tablets.

Letter of Medical Necessity Template

Use this template to write a letter to establish medical necessity, which payers may require for treatment with AUSTEDO XR or AUSTEDO.

Teva Shared Solutions^® HCP Brochure

This brochure provides an overview of support services offered through Shared Solutions, including working with pharmacies to fill prescriptions and managing prior authorization and appeals.

Downloadable resources for your patients with TD

Treatment Tracking Guide

A useful resource for patients as they begin their treatment journey. Patients and their carepartners can use this tracking tool to record when they take their treatment, as well as any changes in their TD.

Patient Brochure

This brochure provides answers to important questions your patients with TD and their carepartners may have when starting treatment.

Teva Shared Solutions^® Patient Brochure

This brochure provides an overview of patient support services offered through Shared Solutions, including help with access and affordability.

Faces of TD: Patient case studies

TD Talks: Informative videos on TD evaluation and treatment

Demystifying EPS: TD Is Distinct—a 3-part series on the importance of differential diagnosis

TD virtual assessments, demonstrated by Dr. Arvinder Walia

For more videos, visit the YouTube page.

EPS, extrapyramidal symptoms; VMAT2, vesicular monoamine transporter 2.

REFERENCE: 1. Solmi M, Pigato G, Kane JM, Correll CU. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2018;12:1215-1238.

Important safety information

Depression and Suicidality in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO XR and AUSTEDO are contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.

Contraindications: AUSTEDO XR and AUSTEDO are contraindicated in patients with Huntington’s disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO XR and AUSTEDO are also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine or valbenazine.

Clinical Worsening and Adverse Events in Patients with Huntington’s Disease: AUSTEDO XR and AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO XR or AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects.

QTc Prolongation: AUSTEDO XR and AUSTEDO may prolong the QT interval, but the degree of QT prolongation is not clinically significant when AUSTEDO XR or AUSTEDO is administered within the recommended dosage range. AUSTEDO XR and AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO XR and AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.

Akathisia, Agitation, and Restlessness: AUSTEDO XR and AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO XR or AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO XR and AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO XR or AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence.

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO XR and AUSTEDO.

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects.

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntington’s disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. Adverse reactions with AUSTEDO XR extended-release tablets are expected to be similar to AUSTEDO tablets.

Please see full Prescribing Information, including Boxed Warning.